Literature DB >> 6508986

Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.

J E Bredesen, P Kierulf.   

Abstract

Highly purified serum albumin did not bind either disopyramide (DP) or mono-N-dealkyldisopyramide (MND). The unbound fraction of DP and MND in highly purified serum alpha 1-acid glycoprotein (AAG) at 0.5 g/l was 57 and 62 and at 2.0 g/l 19 and 30% respectively. Unbound DP and MND were measured in spiked plasma (10 mumol/l of DP or MND), from 60 patients, having AAG concentrations varying from 0.4 to 3.0 g/l. Unbound drug varied from 13 to 58 and from 24 to 62% for DP and MND, respectively, and was inversely related to the plasma concentration of AAG (r = -0.9016, r = -0.9157). A linear relationship was found between the binding ratio (moles bound divided by moles unbound) and the plasma concentration of AAG for both DP (r = 0.9199) and MND (r = 0.9270), whereas no relationship was found between the binding ratios of DP or MND and the plasma concentrations of total protein, albumin, haptoglobin, alpha 1-antitrypsin or the immunoglobulins IgG, IgA or IgM. In patients on DP maintenance therapy, a linear relationship was found between percent unbound DP and the plasma concentration of DP in samples with similar AAG concentrations. Furthermore, a linear relationship was found between the binding ratio of DP and the plasma concentration of AAG in samples with similar DP concentrations. The present findings support the concept that AAG is the major serum protein responsible for the binding of DP and MND.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508986      PMCID: PMC1463556          DOI: 10.1111/j.1365-2125.1984.tb02542.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

2.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

Review 3.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 4.  Pharmacology of commonly used antiarrhythmic drugs and comments on the use of therapeutic drug monitoring.

Authors:  O B Garfein
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

5.  Contamination of albumin by alpha 1-acid glycoprotein.

Authors:  J J Lima; L B Salzer
Journal:  Biochem Pharmacol       Date:  1981-09-15       Impact factor: 5.858

6.  Gas-chromatographic determination of disopyramide and its mono-N-dealkylated metabolite in serum with use of a nitrogen-selective detector.

Authors:  J E Bredesen
Journal:  Clin Chem       Date:  1980-04       Impact factor: 8.327

7.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.

Authors:  J J Lima; H Boudoulas; M Blanford
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

Review 9.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

10.  Plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; E Pike; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more
  11 in total

1.  Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

Authors:  L E Pedersen; J Bonde; N A Graudal; N V Backer; J E Hansen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

Review 2.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

3.  Effect of acute experimental influenza A virus pneumonia on concentration of alpha 1-acid glycoprotein in mouse serum.

Authors:  W Wong; F Y Aoki; A D Friesen; D S Sitar; R J Weselake
Journal:  Inflammation       Date:  1989-12       Impact factor: 4.092

4.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  Kinetics of disopyramide in decreased hepatic function.

Authors:  J Bonde; N A Graudal; L E Pedersen; S Balsløv; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 8.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

9.  Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle.

Authors:  F Vanhoutte; J Vereecke; E Carmeliet; N Verbeke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

10.  Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease.

Authors:  J Bonde; L E Pedersen; H R Angelo; J Trap-Jensen; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.